Abstract: The present disclosure provides a method, device, and system for deploying a wireless headset based on a third-party platform. The method includes: receiving, by a third-party platform, a headset list sent by a base station, and selecting a headset based on the headset list for deployment; after deploying the headset, sending deployment information of the headset and authentication information of the third-party platform to the base station, to enable the base station to feed back an authentication result based on the deployment information and the authentication information; and obtaining a deployment result of the headset based on the authentication result. This reduces a difficulty in deploying a wireless headset and improves universality of deploying the wireless headset.

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. The disclosure describes isolated peptides comprising at least 70% sequence identity to a peptide of one of SEQ ID NOS: 1-107. The peptide may comprise at least 6 contiguous amino acids of a peptide of one of SEQ ID NOS: 1-107. The disclosure also describes a peptide comprising at least 6 contiguous amino acids from a peptide of one of SEQ ID NOS: 1-107, wherein the peptide comprises an alternative splice site junction. Also described is a polypeptide comprising the peptide, pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. The nucleic acids of the disclosure include nucleic acids that are RNA or DNA. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgE mediated disorders.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Abstract: Transcript Enrichment and Quantification Utilizing Isothermally Linear-Amplified Sequencing (TEQUILA-seq) is a versatile, easy-to-implement, and highly cost-effective method utilizing isothermally linear-amplified capture oligos for targeted sequencing. TEQUILA-seq reduces the per-reaction cost of targeted capture by 2-3 orders of magnitude, as compared to a standard commercial solution. When performed on the Oxford nanopore platform for long-read RNA-seq with multiple gene panels of varying sizes, TEQUILA-seq consistently and substantially enriched transcript coverage while preserving transcript quantification. Profiling of full-length transcript isoforms of 468 actionable cancer genes across 40 breast cancer cell lines representing distinct intrinsic subtypes identified transcript isoforms enriched in specific subtypes and discovered novel transcript isoforms in extensively studied cancer genes such as TP53.

Abstract: A solid-liquid separation system having a filter cylinder, a filter cloth laying assembly, an assembly for carrying and moving the filter cylinder, a squeezing assembly, and an assembly for laying a filter cloth, unloading materials and rolling up a filter cloth. The assembly for carrying and moving the filter cylinder is located below the filtering cylinder and includes a working position A and a working position B, and the squeezing assembly is located above the filtering cylinder at the working position B. The filter cloth laying assembly includes a laying and folding component and a dispensing component, and the dispensing component is located above the filter cylinder. The laying and folding component is used for laying a filter cloth in the filter cylinder, and the dispensing component is used for spraying downward materials to be treated onto the filter cloth.

Abstract: The present disclosure is directed to the accurate and high throughput method for screening and identifying antigen-reactive T Cell Receptors (TCRs) capable of triggering effective T-cell activation.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

Abstract: The present disclosure provides a method, device, and system for deploying a wireless headset based on a third-party platform. The method includes: receiving, by a third-party platform, a headset list sent by a base station, and selecting a headset based on the headset list for deployment; after deploying the headset, sending deployment information of the headset and authentication information of the third-party platform to the base station, to enable the base station to feed back an authentication result based on the deployment information and the authentication information; and obtaining a deployment result of the headset based on the authentication result. This reduces a difficulty in deploying a wireless headset and improves universality of deploying the wireless headset.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Abstract: Provided herein are assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12. Also provided herein are recombinant nucleic acids for the improved expression of functional metalloproteinases ADAMTS-7 and nucleic acids for the improved expression of functional metalloproteinases ADAMTS-12. In addition, provided herein are peptide substrates (e.g. FRET substrates) for use in assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12.

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating brain cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.

Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.

Abstract: The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.